Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users.

Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users.
复制标题

DOI:
10.1016/j.jsat.2014.06.006
复制
发表时间:
2015-01
影响因子:
3.9
通讯作者:
Ling, Walter
Ling, Walter
中科院分区:
医学2区
文献类型:
--
作者:
Nielsen, Suzanne;Hillhouse, Maureen;Mooney, Larissa;Ang, Alfonso;Ling, Walter

文献摘要

参考文献

被引文献

相似文献

大多数检测丁丙诺啡的研究都是在海洛因使用者中进行的。很少有研究研究丁丙诺啡对处方阿片类药物使用者的药物治疗。数据来自丁丙诺啡药物治疗和药物管理平台上提供为期16周的行为治疗的随机对照试验。我们比较了海洛因(H,n=54)、处方阿片类药物(PO,n=54)和海洛因+处方阿片类药物(POH,n=71)使用者,以检验PO使用者比海洛因使用者有更好的治疗结果的假设。在联合治疗期间(PO:70%,POH:40%,H:38%,P<0.001)和联合治疗结束时(PO:65%,POH:31%,H:33%,P<0.001),PO组提供了更多的阿片阴性尿药筛选。H组的固位率最低(PO:80%,POH:65%,H:57%,p=0.039)。丁丙诺啡剂量在两组间无显著差异。与那些报告吸食海洛因的人相比,吸毒者在丁丙诺啡药物治疗方面似乎有更好的结果,证实丁丙诺啡药物治疗对吸毒者有效。
Most research examining buprenorphine has been conducted with heroin users. Few studies have examined buprenorphine pharmacotherapy for prescription opioid users. Data were from a randomized controlled trial of behavioral treatment provided for 16 weeks on a platform of buprenorphine pharmacotherapy and medication management. We compared heroin (H, n=54), prescription opioid (PO, n=54) and combination heroin+prescription opioid (POH, n=71) users to test the hypothesis that PO users will have better treatment outcomes compared with heroin users. The PO group provided more opioid-negative urine drug screens over the combined treatment period (PO:70%, POH:40%, H:38%, p<0.001) and at the end of the combined treatment period (PO:65%, POH:31%, H:33%, p<0.001). Retention was lowest in the H group (PO:80%, POH:65%, H:57%, p=0.039). There was no significant difference in buprenorphine dose between the groups. PO users appear to have better outcomes in buprenorphine pharmacotherapy compared to those reporting any heroin use, confirming that buprenorphine pharmacotherapy is effective in PO users.
DOI: 10.1177/002204260503500304
发表时间: 2005-06-01
影响因子: 1.7
作者:
Heinrich, CJ;Fournier, E
通讯作者: Fournier, E
DOI: 10.1016/j.jsat.2011.12.009
发表时间: 2012-10-01
影响因子: 3.9
作者:
Nielsen, Suzanne;Hillhouse, Maureen;Ling, Walter
通讯作者: Ling, Walter
DOI: 10.1038/clpt.1994.71
发表时间: 1994-05-01
影响因子: 6.7
作者:
WALSH, SL;PRESTON, KL;BIGELOW, GE
通讯作者: BIGELOW, GE
DOI: 10.1016/j.drugalcdep.2003.10.012
发表时间: 2004-02-07
影响因子: 4.2
作者:
Brands, B;Blake, J;Busto, U
通讯作者: Busto, U
DOI: 10.1016/s0376-8716(99)00074-5
发表时间: 2000-02-01
影响因子: 4.2
作者:
Amass, L;Kamien, JB;Mikulich, SK
通讯作者: Mikulich, SK